Michael Havert
StrideBio, United States
Vice President, Regulatory affairs
Mike was trained as a virologist and has experience in the development of genetic medicines for the treatment of rare diseases and cancer. Mike recently worked at the CMC/regulatory interface for HSCT gene therapy programs at bluebird bio. Prior to his current position, Mike served as a reviewer in the Gene Therapy Branch at the FDA from 2004-2019. Mike’s accomplishments at FDA include serving as licensing Chair for a genetically modified autologous T-cell immunotherapy and championing the release of new Gene Therapy guidance documents. Prior to joining FDA, Mike received a Ph.D. from the University of Wisconsin, conducted postdoctoral fellowships at Johns Hopkins University and National Institutes of Health.